Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azacitidine maintenance versus placebo plus best supportive care in Chinese patients with acute myeloid leukemia in first remission
CTR20221210Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Bristol Myers Squibb. Started Sep 2022; status: active.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20221210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221210.